Recurrence after surgery in patients with NSCLC.

Surgery remains the only potentially curative modality for early-stage non-small cell lung cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of lung cancer patients develop recurrence, even after curative resection. This review discusses the superiority of surgery, the reasons for recurrence, the timing and pattern of recurrence, the identification of factors related to recurrence, current provisions for treatment and perspectives about surgery for patients with NSCLC.

[1]  M. Vázquez,et al.  Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. , 2003, Chest.

[2]  W. Mutschler,et al.  Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  H. Uramoto,et al.  Simple prophylactic fixation for lung torsion. , 2010, The Annals of thoracic surgery.

[4]  P. Goldstraw,et al.  Surgery in 2013 and beyond. , 2013, Journal of thoracic disease.

[5]  K. Nagai,et al.  Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. , 2011, Chest.

[6]  T. Goya,et al.  Early recurrence after surgical resection in patients with pathological stage I non-small cell lung cancer. , 2009, The Thoracic and cardiovascular surgeon.

[7]  L. Raez,et al.  Gene expression profiling and non-small-cell lung cancer: where are we now? , 2009, Clinical lung cancer.

[8]  I. Jurisica,et al.  Understanding prognostic gene expression signatures in lung cancer. , 2009, Clinical lung cancer.

[9]  L. Marks,et al.  Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  F. Tanaka,et al.  Prediction of recurrence after complete resection in patients with NSCLC. , 2012, Anticancer research.

[11]  G. Pelosi,et al.  Late events and clinical prognostic factors in stage I non small cell lung cancer. , 2002, Lung cancer.

[12]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[13]  Y. Maehara,et al.  Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. , 2010, The Annals of thoracic surgery.

[14]  H. Uramoto,et al.  TS expression predicts postoperative recurrence in adenocarcinoma of the lung. , 2011, Lung cancer.

[15]  L. Crinò,et al.  High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Mirimanoff,et al.  Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). , 2013 .

[17]  V. Kosma,et al.  Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. , 2008, Histology and histopathology.

[18]  N. Wada,et al.  Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. , 2009, Lung cancer.

[19]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[20]  S. Shiono,et al.  Positron Emission Tomography/Computed Tomography and Lymphovascular Invasion Predict Recurrence in Stage I Lung Cancers , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  J. Crowley,et al.  Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[23]  T. Oyama,et al.  Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. , 2010, Lung cancer.

[24]  H. Egami,et al.  No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer. , 1999, Surgery.

[25]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Fountain,et al.  Disease recurrence after resection for stage I lung cancer. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[27]  V. Torri,et al.  Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Tsubota,et al.  Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. , 2013, Interactive Cardiovascular and Thoracic Surgery.

[29]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[30]  T. Oyama,et al.  Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Michael R. Green,et al.  Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) , 2005 .

[32]  J. Luketich,et al.  Widespread Molecular Alterations Present in Stage I Non-Small Cell Lung Carcinoma Fail to Predict Tumor Recurrence , 2003, Modern Pathology.

[33]  A. Lacy,et al.  Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. , 2001, Gastroenterology.

[34]  H. Kato,et al.  Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected nonsmall cell lung cancer: a multicenter prospective study. , 2003, The Annals of thoracic surgery.

[35]  J. Crowley,et al.  Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. , 2000, The Journal of thoracic and cardiovascular surgery.

[36]  A. Gajra,et al.  Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  N. Tsubota,et al.  Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer , 2009, Clinical Cancer Research.

[38]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[39]  Fumihiro Tanaka,et al.  The expression of Ki-67, but not proliferating cell nuclear antigen, predicts poor disease free survival in patients with adenocarcinoma of the lung. , 2011, Anticancer research.

[40]  N. Willich,et al.  Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. , 2008, The Lancet. Oncology.

[41]  Joachim Widder,et al.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study , 2009, Radiation oncology.

[42]  E. Felip,et al.  Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. , 2013, Translational lung cancer research.

[43]  J. Padilla,et al.  Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  H. Kato,et al.  A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). , 2003, The Journal of thoracic and cardiovascular surgery.

[45]  Takayuki Kosaka,et al.  Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  F. Tanaka,et al.  Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. , 2011, Anticancer Research.

[47]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Sonobe,et al.  Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer , 2009, Cancer.

[49]  G. Mælandsmo,et al.  Clinical significance of disseminated tumour cells in non-small cell lung cancer , 2013, British Journal of Cancer.

[50]  R. Onimaru,et al.  Stereotactic Body Radiation Therapy For T1N0M0 Non-small Cell Lung Cancer: First Report for Inoperable Population of a Phase II Trial by Japan Clinical Oncology Group (JCOG 0403) , 2012 .

[51]  Ara A Vaporciyan,et al.  Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  C. Tzen,et al.  Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer , 2007, Medical oncology.

[53]  F. Tanaka,et al.  Clinical significance of IGF1R expression in non-small-cell lung cancer. , 2012, Clinical lung cancer.

[54]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[55]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[56]  B. Milleron,et al.  Association of CK19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. , 2005, European journal of cancer.

[57]  V. Rusch,et al.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. , 2011, The Journal of thoracic and cardiovascular surgery.

[58]  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[59]  Sabine Riethdorf,et al.  Review: Biological relevance of disseminated tumor cells in cancer patients , 2008, International journal of cancer.

[60]  Chung-Ping Hsu,et al.  Clinical significance of bone marrow microinvolvement in nonsmall cell lung carcinoma , 2004, Cancer.

[61]  Fumihiro Tanaka,et al.  The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma. , 2011, Anticancer research.

[62]  Hiroki Shirato,et al.  STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .

[63]  Jonathan R Pollack,et al.  A perspective on DNA microarrays in pathology research and practice. , 2007, The American journal of pathology.

[64]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  S. Knudsen,et al.  Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. , 2010, Cancer research.

[66]  Y. Yatabe,et al.  Surgery for NSCLC in the era of personalized medicine , 2013, Nature Reviews Clinical Oncology.

[67]  G. Scagliotti,et al.  Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. , 2013, Translational lung cancer research.

[68]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[69]  Biao He,et al.  A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies , 2012, The Lancet.

[70]  O. Dalesio,et al.  Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review , 2007, The Lancet.

[71]  H. Uramoto,et al.  A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. , 2010, Anticancer research.

[72]  M. Tsuboi,et al.  Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). , 2012 .

[73]  B. Weynand,et al.  Bone marrow micrometastasis might not be a short-term predictor of survival in early stages non-small cell lung carcinoma. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[74]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  I. Fukuda,et al.  Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases , 2002, International Journal of Clinical Oncology.

[76]  T. Oyama,et al.  Prediction of pulmonary complications after a lobectomy in patients with non-small cell lung cancer , 2001, Thorax.

[77]  R. Weichselbaum,et al.  Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[78]  H. Uramoto,et al.  Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC. , 2010, Anticancer research.

[79]  M. Okumura,et al.  Clinical outcome of resected solid-type small-sized c-stage IA non-small cell lung cancer. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[80]  T. Oyama,et al.  Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. , 2011, The Journal of thoracic and cardiovascular surgery.

[81]  R. Govindan,et al.  Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.